Hypertension as a risk factor for aspirin and clopidogrel resistance in patients with stable coronary artery disease

Clinical and Applied Thrombosis/Hemostasis

Volumn 20, Issue 7, 2014, Pages 749-754

  Akturk, Ibrahim Faruk ^a   Caglar, Fatma Nihan ^a   Erturk, Mehmet ^a   Tuncer, Nilgun ^a   Yalcin, Ahmet Arif ^a   Surgit, Ozgur ^a   Uzun, Fatih ^a   Caglar, Ilker Murat ^a  

^a Istanbul Mehmet Akif Ersoy Thoracic Cardiovascular Surgery ducation and Research Hospital   (Turkey)

Author keywords

Aspirin resistance; Clopidogrel resistance; Coronary artery disease; Hypertension

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; URIC ACID; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ADULT; ARTICLE; BLOOD PRESSURE MONITOR; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; CORRELATION ANALYSIS; FEMALE; HUMAN; HYPERTENSION; IMPEDANCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; URIC ACID BLOOD LEVEL; AGED; ANALOGS AND DERIVATIVES; BLOOD; DRUG RESISTANCE; PERCUTANEOUS CORONARY INTERVENTION; STENT;

ADULT; AGED; ASPIRIN; CORONARY ARTERY DISEASE; DRUG RESISTANCE; FEMALE; HUMANS; HYPERTENSION; MALE; MEAN PLATELET VOLUME; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; RISK FACTORS; STENTS; TICLOPIDINE;

EID: 84908674403     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029613481102     Document Type: Article

References (33)

1. Kim H, Lee HK, Han K, Jeon H-K. Prevalence and risk factors for aspirin and clopidogrel resistance in patients with coronry artery disease. Ann Clin Lab Science. 2009;39(3):289-294.
2. Wiviott SD, Antman EM. Clopidogrel resistanc: a new chapter in a fast-moving story. Circulation. 2004;109(25):304-3067.
3. Pamukcu B. A review of aspirin resistance; definition, possible mechanisms, detection with platelet function tests and its clinical outcomes. J Thromb Thrombolysis. 2007;23(3):213-222.
4. Ozben B, Tanrikulu AM, Ozben T, Caymaz O. Aspirin resistance in hypertensive patients. J Clin Hypertens. 2010;12(9):714-720.
5. Watala C, Pluta J, Golanski J, et al. Increased protein glycation in diabtes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med. 2005;83(2):148-158.
6. Anfossi G, Russo I, Trovati M. Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome. Curr Vasc Pharmacol. 2008;6(4):313-328.
7. Fateh-Moghadan S, Plöckinger U, Cabeza N, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol. 2005;42(2):99-103.
8. Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Järvinen H. Obesity is ssocited with impaired platelet-inhibitory effect of acetylslicylic acid in nondiabetic subjects. Int J Obes Relt Metab Disord. 2003;27(8):907-911.
9. Kahraman G, Sahin T, Kilic T. The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome. Int J Cardiol. 2007;115(3):391-396.
10. Friend M, Vucenik I, Miller M. Research pointers: platelet responsiveness to aspirin in patients with hyperlipidemia. BMJ. 2003;326(7380):82-83.
11. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implictions for the use of ASA clinically. Canad J Cardiol. 1995;11(3):221-227.
12. Görlinger K, Jambor C, Hanke AA, et al. Perioperative coagulation management and control of platelet transfusion by point-of-care platelet function analysis. Transfus Med Hemother. 2007;34: 396-411.
13. Gurbel P, Tantry US. Clopidogrel resistance? Thromb Res. 2007; 120(3):311-321.
14. Vlachojanis GJ, Dimitropoulos G, Alexopoulos D. Clopidogrel resistance: current aspects and future directions. Hellenic J Cardiol. 2011;52(3):236-245.
15. Motovska Z, Widimsky P, Marinov I, Petr R, Hajkova J, Kvasnicka J. Clopidogrel resistance "Live"-the risk of stent thrombosis should be evaluated before procedures. Thrombosis J. 2009;7:1-6.
16. Gasparovic H, Petricevic M, Kopjar T, Djuric Z, Svetina L, Biocina B. Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial. 2012;13(1):148.
17. Fitzgerald DJ, Maree A. Aspirin and clopidogrel resistance. Hematology Am Soc Hematol Educ Program. 2007:114-120.
18. Altman R, Luciardi HL, Muntner J, Herrra RN. The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb J. 2004;2(1):1-8.
19. Wang CB, Hu DY, Shi XB, Zhu ZY, Zhu JY, Yang JG. Aspirin resistance in patients taking small dose of aspirin. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2006;18(4):219-223.
20. Abci A, Caliskan M, Bayram F, et al. A new definition of aspirin non-responsiveness by platelet function analyzer-100 and its predictors. Platelets. 2000;17(1):7-13.
21. Feher G, Kolti K, Papp E. Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables. Drugs Aging. 2006;23(7):559-567.
22. Mosorjakova D, Paluch Z, Alusik S. Aspirin resistance. Bratisl Lek Listy. 2007;108(1):7-13.
23. Desai AA, Nayak VK, Desai NK, Gupta KC. Effect of nifedipine and aspirin on platelet aggregation: A study in hypertensive patients and normal volunteers. Indian J of Pharmacol. 1995; 27(3):167-170.
24. Altman R, Seazziota A, Dujovne C. Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation. Clin Pharmacol Ther. 1988;44(3):320-325.
25. Moser L, Callahan KS, Cheung AK, Stoddart GJ, Munger MA. ACE inhibitor effects on platelet function in stages I-II hypertension. J Cardiovasc Pharmacol. 1997 Oct; 30(4):461-7.
26. Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T. Angiotensin II AT1 rceptor antgonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension. 2002; 40(4):521-527.
27. Winter K, Trap-Jensen J. Effects of three beta-blockers with different pharmacodynamic properties on platelet aggregation and platelet and plasma cyclic AMP. Eur J Clin Pharmacol. 1988; 35(1):17-20.
28. Punda A, Polic S, Rumboldt Z, Bagatin J, Markovic V, Lukin A. Effects of atenolol and proprnolol on platelet aggregation in moderate essentials hyprtension: randomized crossover trial. Croat Med J. 2005;46(2):219-224.
29. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and th incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J AmColl Cardiol. 2005;45(9):1392-1396.
30. Von Beckerath, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A. Absorbtioni metbolization, and antiplatelet effects of 300-, 600, - and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary stenting and antithrombotic regimen: Choose betwn 3 high oral doses for immediate clopidogrel effect) trial. Circulation. 2005;112(19):2946-2950.
31. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003: 107(23):2908-2913.
32. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel tratment. Diabetes. 2005;54(8):2430-2435.
33. Prabhakaran S, Wells KR, Lee VH, Flaherty CA, Lopes DK. Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol. 2008;29(2): 281-285.